Bioniche Life Sciences Inc. 25 Years
Contact Us Careers
Home Newsroom
In the News

April 15, 2014
Vétoquinol and Bioniche Life Sciences Inc. Close Sale of Bioniche Animal Health Business

April 14, 2014
Bioniche Life Sciences Inc. Shareholders Approve Sale of Animal Health Business

Investors

Latest TSX stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.


Newsroom

One Health News Release

Further Research Studies Support E. coli Cattle Vaccine Efficacy

14/03/05

-- significant reduction in bacteria shed by feedlot cattle; reduction in colonization --

BELLEVILLE ON – March 14, 2005 – Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that positive results were seen in the three latest University of Nebraska feedlot studies utilizing the E. coli O157:H7 cattle vaccine.

In one study, with cattle receiving three doses of vaccine, there were 73% fewer animals detectably shedding E. coli O157:H7 bacteria in their manure. Another three-dose study analyzed colonization in the terminal rectal junction in the cattle, where the bacteria are known to colonize and reproduce. After vaccination, 97% fewer animals had detectable bacterial colonization. A third study, involving 19 feedlots and 21,691 cattle, demonstrated that the vaccine was effective in commercial feedlot settings. In that study, vaccinated cattle were 75% less likely to have detectable bacterial colonization.

“The studies were conducted in Nebraska during the summers of 2003 and 2004,” said Dr. Rodney Moxley, Professor and Interim Department Head of the Department of Veterinary and Biomedical Sciences at the University of Nebraska - Lincoln. “This is the third year of data generated through clinical trials of this vaccine, and we are seeing consistently satisfactory results in terms of its effectiveness in feedlot settings where E. coli O157:H7 bacteria are prevalent.” The results of the latest University of Nebraska studies will be published in a peer-reviewed journal later this year.

Bioniche is the commercialization and marketing partner in a strategic alliance with the University of British Columbia, the Vaccine & Infectious Disease Organization at the University of Saskatchewan, the University of Nebraska, Technology Partnerships Canada, and the Alberta Research Council.

“The consistent results in the University of Nebraska efficacy studies give us confidence as we move toward licensing of this important vaccine,” added Graeme McRae, President & CEO of Bioniche Life Sciences Inc. “These data generated by the University of Nebraska will be included in our upcoming submissions to the Canadian Food Inspection Agency (CFIA) and the United States Department of Agriculture (USDA) as part of the regulatory process.”

###


Back

Categories:
All Releases
Archived Releases
Animal Health
Corporate
Financial
Human Health
One Health

Copyright 2004, Bioniche Life Sciences Inc. All rights reserved  |  Legal Disclaimer  |  Privacy Policy